Hims & Hers Health Inc. saw its stock price plummet by 5.03% during intraday trading on Thursday. The sharp decline followed recent announcements regarding the expansion of its platform to include major drugmakers' products.

Analysis suggests the sell-off reflects investor concerns over the company's evolving and potentially diminished role in the lucrative GLP-1 weight-loss drug market. According to a Barron's report, Hims & Hers is losing its competitive edge as major pharmaceutical companies like Eli Lilly and Novo Nordisk move to reclaim market share that the telehealth provider gained during recent drug shortages.

The company recently announced agreements allowing providers on its platform to prescribe medications fulfilled by independent pharmacies, including Eli Lilly's LillyDirect. While this expands patient access, analysts note it highlights a strategic shift where Hims acts more as an intermediary "front door" rather than a differentiated service provider, especially after its exit from large-scale drug compounding. This has raised questions about the company's future market position and profitability as the unique supply dynamics that fueled its earlier growth have subsided.